## Martina Frodlund

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1207717/publications.pdf

Version: 2024-02-01

759055 940416 26 452 12 16 citations h-index g-index papers 26 26 26 699 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Longitudinal Analysis of Anti-cardiolipin and Anti- $\hat{l}^2$ 2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. Frontiers in Medicine, 2021, 8, 646846.	1.2	4
2	SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. Frontiers in Immunology, 2021, 12, 724047.	2.2	13
3	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. Journal of Clinical Medicine, 2021, 10, 3820.	1.0	4
4	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 254-261.	0.5	30
5	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. Clinical and Experimental Immunology, 2020, 199, 245-254.	1.1	29
6	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 363-369.	0.5	76
7	P23â€Longitudinal antinuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of swedish cases with recent-onset disease. , 2020, , .		O
8	P86â€The NCF1–339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. , 2020, , .		1
9	P89â€Epigenome-wide association study reveals differential DNA methylation in systemic lupus erythematosus patients with a history of ischemic heart disease. , 2020, , .		O
10	P33â€Cytokine and autoantibody profiles during treatment with belimumab in patients with systemic lupus erythematosus. , 2020, , .		0
11	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2020, 21, 3463.	1.8	26
12	Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus, 2020, 29, 625-630.	0.8	9
13	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. Lupus, 2019, 28, 1261-1272.	0.8	22
14	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2019, 21, 259.	1.6	16
15	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 1063-1069.	0.5	41
16	PS4:71â€lga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. , 2018, , .		0
17	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clinical and Experimental Immunology, 2018, 194, 27-38.	1.1	16
18	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opinion on Biological Therapy, 2018, 18, 911-920.	1.4	21

#	Article	lF	CITATIONS
19	S4A:5â€High genetic risk score is associated with organ damage in systemic lupus erythematosus. , 2018, , .		1
20	OP0362â€Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. , 2018, , .		1
21	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 343-351.	2.5	80
22	103â€Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. , 2017, , .		0
23	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. Lupus Science and Medicine, 2017, 4, e000225.	1.1	18
24	SAT0233â€High anti-dsdna content in sle immune complexes is associated with clinical remission following belimumab treatment. , 2017, , .		0
25	THU0345â€Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and β2-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 312.1-312.	0.5	0
26	Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open, 2013, 3, e003608.	0.8	44